FibroBiologics announced on May 11, 2026, expansion of its fibroblast platform to target Hantavirus pulmonary syndrome (HPS), building on ARDS preclinical data.
HPS causes severe lung damage via inflammatory responses, endothelial dysfunction, and pulmonary fibrosis; no approved treatments exist, with 35-40% mortality.
Preclinical ARDS studies show fibroblasts reduce inflammation, restore endothelial integrity, and promote tissue repair—mechanisms applicable to HPS.
Company evaluating platform in Hantavirus models, focusing on cytokine modulation and endothelial permeability.
Plans exploratory discussions with regulators for clinical development pathway in HPS patients.